The Government of India is looking at getting 300-400 million doses of coronavirus vaccine by July, which is being developed by an international health consortium that includes Punes Serum Institute of India (SII), a top official said here on Saturday.
The Covidshield vaccine is being developed jointly by Oxford University, AstraZeneca, and SII. SII is the world's largest vaccine manufacturer, where Prime Minister Narendra Modi spent time on Saturday evening to check on the vaccine status.
Serum Institute of India (SII) CEO Adar Poonawalla said on Saturday that the Pune-based pharma company is in the process of applying for emergency use authorization of 'Covishield' in the next two weeks.
"I am delighted to hear that, Covishield, a low-cost, logistically manageable & soon to be widely available, #COVID19 vaccine, will offer protection up to 90% in one type of dosage regime and 62% in the other dosage regime. Further details on this, will be provided this evening," Adar Poonawalla had said in a tweet on November 23.
Modi was accorded a warm welcome by SII's Founder-Chairman Cyrus Poonawalla, CEO Adar Poonawalla, his wife and Executive Director Natasha A. Poonawalla, and other officials.
Currently, the SII is producing around 50-60 million doses which would be scaled up to 100 million by January 2021, said SII CEO Adar Poonawalla in a video-conference with the media.
"Presently, we have nothing in writing from the government on how many doses it will buy, but the indication is that the need would be for around 300-400 million doses by July 2021," Poonawalla said, shortly after the PM's visit at SII's sprawling manufacturing facility in Hadapsar, on the outskirts of Pune.
The SII discussed with the PM the implementation plan for the vaccine after getting the emergency use approval. After that, the Health Ministry will roll out the doses in the first and second quarter of 2021, subject to SII making its submissions and securing the necessary clearances.
He said the vaccine trials have got good efficacy results with "zero hospitalization" among those who took it and those who had caught the virus were not infecting it, with plans to extend the trials to persons below 18 years of age, said Poonawalla.
The CEO added that the company honchos were impressed by the PM's "good knowledge of vaccines and its production", saying "there was very little he needed to be explained".
The SII CEO added that the company's priority is India since the Covidshild vaccine will be initially distributed domestically.
Also Read: PM Modi reaches Pune’s Serum Institute, concludes his 3-city tour
"Then we shall look at the COVAX countries which are mainly in Africa, while the UK and European markets are being handled by AstraZeneca and Oxford University. Our priority is India and COVAX countries," Poonawalla asserted.
The PM came to the SII during his daylong flying visits to three cities where he visited the facilities engaged in developing the Covid-19 vaccine, including Bharat Biotech in Hyderabad and Zydus Biotech Park in Ahmedabad.
During his visit to SII, Modi went around the plant premises, including the state-of-the-art new facility which can handle the manufacturing of one billion doses, accompanied by senior officials of the company, who explained the details of the vaccine manufacturing process to the Prime Minister.
"Had a good interaction with the team at Serum Institute of India. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing. Also took a look at their manufacturing facility," Modi tweeted after his visit, sharing pictures.